Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced CLL, defined as no response or progressive disease during standard nucleoside analogue based regimen; or, evidence of progressive disease within 24 months of completion of nucleoside analogue regimen; or, intolerance to fludarabine; or, failure to achieve complete remission following salvage regimen.~* no sites of adenopathy \> 5cm~* (8/8) HLA matched related or unrelated donor available.~* Must have prior banked tumor, collected by peripheral blood draw, leukapheresis, bone marrow biopsy or by lymph node dissection, per DF/HCC protocol 06-200~* ECOG performance status 0-2~Exclusion Criteria:~* Serum creatinine greater than or equal to 2.0mg/dl~* ALT or AST greater than or equal to 3x ULN~* Total bilirubin greater than or equal to 2.0mg/dl (except for patients with Gilbert's syndrome)~* Cardiac ejection fraction greater than or equal to 30%~* HIV infection~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GM-K562 Vaccine (Type: EXPERIMENTAL): Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).